Meeting
2022 ASCO Annual Meeting
Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial.
Authors
Shin Nishio
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Fukuoka, Japan
Shin Nishio , Mayu Yunokawa , Koji Matsumoto , Kazuhiro Takehara , Kosei Hasegawa , Yasuyuki Hirashima , Hidenori Kato , Hiroki Ikezawa , Maiko Nomoto , Seiichi Hayato , Yohei Otake , Takuma Miura , Kan Yonemori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03386942
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5513)
DOI
10.1200/JCO.2022.40.16_suppl.5513
Abstract #
5513
Poster Bd #
392
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid tumors.
First Author: Toshio Shimizu
Poster
2023 ASCO Annual Meeting
A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.
First Author: Stephanie Gaillard
Poster
2023 ASCO Annual Meeting
Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer.
First Author: Nehal J. Lakhani
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001).
First Author: Andrew L. Coveler